Vol. 6 No. 3 (2026)
Reimbursement Reviews

Bevacizumab

decorative image of the issue cover

Published March 23, 2026

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses bevacizumab, 100 mg and 400 mg vials (25 mg/mL solution for injection).
  • Indication under consideration for reimbursement: in combination with chemotherapy in the second or later lines of therapy for patients with recurrent or metastatic endometrial cancer.